Top Markets
#1 Pleasing Gold Pleasing Gold +601.59%
#2 Islamic Coin Islamic Coin +154.12%
#3 PulseChain PulseChain +52.83%
#4 BOOK OF MEME BOOK OF MEME +41.48%
#5 DogBull DogBull +36.81%
#6 Neiro Neiro +24.76%
#7 Nockchain Nockchain +22.48%
#8 ORDI ORDI +19.01%
#9 SkyAI SkyAI +16.82%
#10 Monad Monad +16.62%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Bio Preventive Medicine Corp. Bio Preventive Medicine Corp.

Bio Preventive Medicine Corp.

6810
Rank in Stocks #27172
Bio Preventive Medicine Corp., a biotechnology firm currently in the clinical... Bio Preventive Medicine Corp., a biotechnology firm currently in the clinical development phase, specializes in the proactive identification and mitigation of various illnesses. The company develops comprehensive strategies for the prevention, screening, and ongoing oversight of chronic conditions and cancer treatment. A key offering is the DNlite test, a suite of proprietary and medically validated non-intrusive urine analyses designed to aid in the management of diabetic kidney disease, encompassing specific products like DNlite-IVD103 and DNlite-DN_Score. Established in 2014, its main operations are located in Zhubei, Taiwan.
Share Price
$0.70116857
Market Cap
$34.67M
Change (1 day)
-1.78%
Change (1 year)
-18.30%
Country
TW
Trade Bio Preventive Medicine Corp. (6810)

Category

Healthcare
Revenue for Bio Preventive Medicine Corp. (6810)
Revenue in Aug 2026 TTM: 0
According to Bio Preventive Medicine Corp. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Bio Preventive Medicine Corp. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH